Once-monthly Ibandronate for postmenopausal Osteoporosis: Review of a new dosing regimen

Clinical Therapeutics

Volumn 28, Issue 4, 2006, Pages 475-490

  Pyon, Eunice Y ^a  

^a LONG ISLAND UNIVERSITY   (United States)

Author keywords

bisphosphonate; ibandronate; intermittent; monthly; postmenopausal osteoporosis

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CLODRONIC ACID; FLUORIDE; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE; PLACEBO; RALOXIFENE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE RADIOGRAPHY; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; DUODENITIS; DUODENUM ULCER; DYSPEPSIA; EYE INFLAMMATION; FEMUR NECK; FLU LIKE SYNDROME; GASTRIC ULCER BLEEDING; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPOCALCEMIA; KIDNEY FUNCTION; LIVER DISEASE; LIVER FUNCTION; LUMBAR SPINAL CORD; MANAGED CARE ORGANIZATION; MEDLINE; MELENA; NAUSEA; NONHUMAN; OSTEOMYELITIS; OVARIECTOMY; PATIENT COMPLIANCE; PATIENT POSITIONING; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZATION; RAT STRAIN; STATISTICAL ANALYSIS; TABLET FORMULATION; VERTEBRA FRACTURE; AGED; ECONOMICS; FEMALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW;

AGED; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE III; DIPHOSPHONATES; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 33745253417     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.04.006     Document Type: Article

References (82)

1. Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 94 (1993) 646-650
2. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 843 (1994) 1-129.
3. Diet, nutrition and the prevention of chronic diseases. World Health Organ Tech Rep Ser. 916 (2003) 1-149
4. Available at:. National Osteoporosis Foundation. Advocacy News & Updates. America's Bone Health. The State of Osteoporosis and Low Bone Mass. Accessed (August 30, 2005). http://www.nof.org/advocacy/prevalence/
5. Bone Health and Osteoporosis: A Report of the Surgeon General (October 14, 2004), US Dept of Health and Human Services, Washington, DC
6. Cummings S.R., and Melton L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet. 359 (2002) 1761-1767
7. Leibson C.L., Tosteson A.N., Gabriel S.E., et al. Mortality, disability, and nursing home use for persons with and without hip fracture: A population-based study. J Am Geriatr Soc. 50 (2002) 1644-1650
8. Richmond J., Aharonoff G.B., Zuckerman J.D., and Koval K.J. Mortality risk after hip fracture. 2003. J Orthop Trauma. 17 Suppl 8 (2003) S2-S5
9. Tosteson A.N. Economic impact of fractures. In: Orwoll E.S. (Ed). Osteoporosis in Men: The Effects of Gender on Skeletal Health (1999), Calif Academic Press, San Diego 15-27
10. Greenblatt D. Treatment of postmenopausal osteoporosis. Pharmacotherapy 25 (2005) 574-584
11. Pande I., and Hosking D.J. Oral antiresorptive therapy. Curr Rheumatol Rep. 7 (2005) 71-77
12. Kleerekoper M. Prevention of postmenopausal bone loss and treatment of osteoporosis. Semin Reprod Med. 23 (2005) 141-148
13. O'Connell M.B., and Seaton T.L. Osteoporosis and osteomalacia. In: Dipiro J.T., Talbert R.L., and Yee G.C. (Eds). Pharmacotherapy: A Pathophysiologic Approach. 6th ed. (2005), McGraw-Hill, New York, NY 1645-1669
14. Delmas P.D. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol. 17 (2005) 462-466
15. Dooley M., and Balfour J.A. Ibandronate. Drugs 57 (1999) 101-108
16. (October 13, 2005). http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseacti on=Search.Overview&DrugName=BONIVA
17. Bauss F., and Russell R.G. Ibandronate in osteoporosis: Preclinical data and rationale for intermittent dosing. Osteoporos Int. 15 (2004) 423-433
18. Miller P.D. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: The emerg ing role of intermittent therapy. Clin Ther. 27 (2005) 361-376
19. Muhlbauer R.C., Bauss F., Schenk R., et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res. 6 (1991) 1003-1011
20. Barrett J., Worth E., Bauss F., and Epstein S. Ibandronate: A clinical pharmacological and pharmacokinetic up date. J Clin Pharmacol. 44 (2004) 951-965
21. Bauss F., Endele E., Besenfelder E., and Hoelck J.P. Ibandronate: Serum kinetics, tissue distribution and bind ing to bone following intravenous bolus injection. Calcif Tissue Int. 70 (2002) 289-290
22. Monier-Faugere M.C., Geng Z., Paschalis E.P., et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: Effects on bone morphometry and mineral properties. J Bone Miner Res. 14 (1999) 1768-1778
23. Smith S.Y., Recker R.R., Hannan M., et al. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 32 (2003) 45-55
24. Chestnut III C.H., Skag A., Christiansen C., et al., Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 19 (2004) 1241-1249
25. Reginster J.Y., Wilson K.M., Dumont E., et al. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: Results from the monthly oral pilot study. J Clin Endocrinol Metab. 90 (2005) 5018-5024
26. Miller P.D., McClung M.R., Macovei L., et al. Monthly oral ibandronate therapy in postmenopausal osteo porosis: 1-Year results from the MOBI LE study. J Bone Miner Res. 20 (2005) 1315-1322
27. Epub. Reginster J.Y., Adami S., Lakatos P., et al. Efficacy and tolerability of oncemonthly oral ibandronate in post menopausal osteoporosis: 2-Year results from the MOBILE study. Jan 26. Ann Rheum Dis. (2006)
28. Rüs B.J., Ise J., von Stein T., et al. Ibandronate: A comparison of oral daily dosing versus intermittent dos ing in postmenopausal osteoporosis. J Bone Miner Res. 16 (2001) 1871-1878
29. Stakkestad J.A., Benevolenskaya L.I., Stepan J.J., et al., Ibandronate Intravenous Study Group. Intravenous ibandronate injections given every three months: A new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis. 62 (2003) 969-975
30. Adami S., Felsenberg D., Christiansen C., et al. Efficacy and safety of ibandronate given by intravenous injec tion once every 3 months. Bone 34 (2004) 881-889
31. Bauss F., Wagner M., and Hothorn L.H. Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. J Rheumatol 29 (2002) 990-998
32. Bauss F., Lalla S., Endele R., and Hothorn L.A. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol. 29 (2002) 2200-2208
33. Muller R., Hannan M., Smith S.Y., and Bauss F. Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey. J Bone Miner Res. 19 (2004) 1787-1796
34. Licata A.A. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother. 39 (2005) 668-677
35. Boniva [package insert] (2005), Roche Pharmaceuticals, Nutley, NJ
36. Tanko L.B., McClung M.R., Schimmer R.C., et al. The efficacy of 48-week oral ibandronate treatment in post menopausal osteoporosis when taken 30 versus 60 minutes before breakfast. Bone 32 (2003) 421-426
37. Poster presented at. McClung M.R., Drezner M.K., Reginster J.Y., et al. Once-monthly oral ibandronate is at least as effec tive as daily oral ibandronate in postmenopausal osteoporosis: 2-Year findings from MOBILE. Nashville, Tenn. 27th Annual Meeting of the American Society for Bone and Mineral Research (September 23-27, 2005)
38. Poster presented at. Miller P.D., Kendler D.L., Garnero P., et al. Once-monthly oral ibandronate effectively normalizes biochemical markers of bone resorption in postmenopausal osteoporosis: MOBILE 2-year analysis. Nashville, Tenn. 27th Annual Meeting of the American Society for Bone and Mineral Research (September 23-27, 2005)
39. Poster presented at:. Reckner R.R., Luckey M., Stakkestad J.A., et al. Large proportions of women with postmenopausal osteo porosis respond to once-monthly oral ibandronate: 2-Year results from MOBILE. Nashville, Tenn. 27th Annual Meeting of the American Society for Bone and Mineral Research (September 23-27, 2005)
40. Nashville, Tenn. Cosman F., McClung M.R., Rosen C.J., et al. Rationale and design of the MOTION study (Monthly Oral Therapy with Ibandronate for Osteoporosis iNtervention). Poster presented at 27th Annual Meeting of the American Society for Bone and Mineral Research (September 23-27, 2005)
41. Schnitzer T., Bone H.G., Crepaldi G., et al., Alendronate OnceWeekly Study Group. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano) 12 (2000) 1-12
42. Brown J.P., Kendler D.L., McClung M.R., et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 71 (2002) 103-111
43. Fosamax [package insert] (2005), Merck & Co, Inc, Whitehouse Station, NJ
44. Actonel [package insert] (2005), Procter & Gamble Pharmaceuticals, Inc, Cincinnati, Ohio
45. Poster presented at:. Lewiecki E.M., Emkey R., Adami S., et al. Once-monthly oral ibandronate is safe and well tolerated in women with postmenopausal osteoporosis: MOBILE 2-year analysis. Nashville, Tenn. 27th Annual Meeting of the American Society for Bone and Mineral Research (September 23-27, 2005)
46. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bis phosphonates: A review of 63 cases. J Oral Maxillofac Surg. 62 (2004) 527-534
47. [published correction ap pears in N Engl J Med. 2005;353: 2728]. Maerevoet M., Martin C., and Duck L. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 353 (2005) 99-102
48. Bagan J.V., Murillo J., Jimenez Y., et al. Avascularjaw osteonecrosis in association with cancer chemotherapy: Series of 10 cases. J Oral Pathol Med. 34 (2005) 120-123
49. Available at:. ODS postmarketing safety review. Pamidronate, zoledronic acid, alendronate, risedronate. Accessed (October 10, 2005). http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005_4095_B2_03_04
50. Yood R.A., Emani S., Reed J.I., et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int. 14 (2003) 965-968
51. McCombs J.S., Thiebaud P., McLaughlin-Miley C., and Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48 (2004) 271-287
52. Poster presented at:. Boccuzzi S.J., Foltz S.H., Omar M.A., et al. Adherence and persistence associated with the pharmacologic treatment of osteoporosis. Orlando, Fla. 39th ASHP Midyear Clinical Meeting and Exhibits (December 5-9, 2004)
53. Tosteson A.N., Grove M.R., Hammond C.S., et al. Early discontinuation of treatment for osteoporosis. Am J Med. 115 (2003) 209-216
54. Reginster J.Y., and Lecart M.P. Treatment of osteoporosis with bisphosphonates: Do compliance and persis tence matter?. Business Briefings: LongTerm Healthcare. (2004) 1-9
55. Richter A., Anton S.E., Koch P., and Dennett S.L. The impact of reducing dose frequency on health outcomes. Clin Ther. 25 (2003) 2307-2335
56. Recker R.R., Gallagher R., and MacCosbe P.E. Effect of dosing frequency on bisphosphonate medication adher ence in a large longitudinal cohort of women. Mayo Clin Proc. 80 (2005) 856-861
57. Poster presented at:. Emkey R., Binkley N., Seidman L., and Rosen C. BALTO I: Women treated for osteoporosis rate preference and convenience for once-monthly ibandronate versus once-weekly alendronate. Nashville, Tenn. 27th Annual Meeting of the American Society for Bone and Mineral Research (September 23-27, 2005)
58. Emkey R., Koltun W., Beusterien K., et al. Patient preference for oncemonthly ibandronate versus once weekly alendronate in a randomized, open-label, cross-over trial: The Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin. 21 (2005) 1895-1903
59. De Cock E., Hutton J., Canney P., et al. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. Clin Ther. 27 (2005) 1295-1310
60. De Cock E., Hutton J., Canney P., et al. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. Support Care Cancer 13 (2005) 975-986
61. Poster presented at:. Ettinger B., Earnshaw S.R., Graham C.N., et al. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: Implications of improved persistence with ibandronate. Nashville, Tenn. 27th Annual Meeting of the American Society for Bone and Mineral Research (September 23-27, 2005)
62. Abstract PL6. Caro J.J., Ishak K.J., Huybrechts K.F., et al. Clinical and economic impact of adherence to osteoporosis medication. Osteoporos Int. 14 Suppl 7 (2003) S2-S3
63. Red Book: August 2005 Update (2005), Red Book, Montvale, NJ
64. 2005 Red Book (2005), Red Book, Montvale, NJ
65. [published correction appears in J Clin Endocrinol Metab. 2001;86:938]. Black D.M., Thompson D.E., Bauer D.C., et al., Fracture Intervention Trial (FIT) Research Group. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab. 85 (2000) 4118-4124
66. Harris S.T., Watts N.B., Genant H.K., et al., Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA 282 (1999) 1344-1352
67. Rosen C.J., Hochberg M.C., Bonnick S.L., et al., Fosamax Actonel Comparison Trial Investigators. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study. J Bone Miner Res. 20 (2005) 141-151
68. Miller P.D., Hochberg M.C., Wehren L.E., et al. How useful are measures of BMD and bone turnover?. Curr Med Res Opin. 21 (2005) 545-554
69. Eastell R., and Delmas P.D. How to interpret surrogate markers of efficacy in osteoporosis. J Bone Miner Res. 20 (2005) 1261-1262
70. Khosla S. Surrogates for fracture endpoints in clinical trials. J Bone Miner Res. 18 (2003) 1146-1149
71. Felsenberg D., and Boonen S. The bone quality framework: Determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther. 27 (2005) 1-11
72. Guyatt G.H., Cranney A., Griffith L., et al. Summary of meta-analyses of therapies for postmenopausal os teoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin North Am. 31 (2002) 659-679
73. Wasnich R.D., and Miller P.D. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endrocrinol Metab. 85 (2000) 231-236
74. Hochberg M.C., Greenspan S., Wasnich R.D., et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endrocrinol Metab 87 (2002) 1586-1592
75. Epstein S. The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Clin Proc. 80 (2005) 379-388
76. Miller P.D. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporos Rep. 3 (2005) 103-110
77. Poster presented at. Lindsay R., Magowan S., Miller P., et al. Treatment-related changes in BMD are not associated with the occurrence of a fragility fracture while on risedronate therapy. Nashville, Tenn. 27th Annual Meeting of the American Society for Bone and Mineral Research (September 23-27, 2005)
78. Tripathy D., Lichinitzer M., Lazarev A., et al., MF 4434 Study Group. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: Efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol. 15 (2004) 743-750
79. Body J.J., Diel I.J., Bell R., et al. Oral ibandronate improves bone pain and preserves quality of life in pa tients with skeletal metastases due to breast cancer. Pain 111 (2004) 306-312
80. Body J.J., Diel I.J., Lichinitser M.R., et al., MF 4265 Study Group. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 14 (2003) 1399-1405
81. Diel I.J., Body J.J., Lichinitser M.R., et al., MF 4265 Study Group. Improved quality of life after long term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer. 40 (2004) 1704-1712
82. Tripathy D., Body J.J., and Bergstrom B. Review of ibandronate in the treatment of metastatic bone disease: Experience from phase III trials. Clin Ther. 26 (2004) 1947-1959